BNT162b2 mRNA SARS-CoV-2 vaccination does not cause upregulation of endothelial activation markers or hypercoagulability: A prospective, single-arm, longitudinal study.
作者信息
Lim Xin Rong, Leung Bernard PuiLam, Sum Christina Lai Lin, Lim Gek Hsiang, Chua Choon Guan, Tu Tian Ming, Ramanathan Kollengode, Huang Mei Yan, Howe Hwee Siew, Fan Bingwen Eugene
机构信息
Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore.
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
出版信息
Am J Hematol. 2022 Apr;97(4):E141-E144. doi: 10.1002/ajh.26462. Epub 2022 Jan 19.
Abstract
摘要
相似文献
1
BNT162b2 mRNA SARS-CoV-2 vaccination does not cause upregulation of endothelial activation markers or hypercoagulability: A prospective, single-arm, longitudinal study.
Am J Hematol. 2022 Apr;97(4):E141-E144. doi: 10.1002/ajh.26462. Epub 2022 Jan 19.
2
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Lancet Infect Dis. 2022 Jan;22(1):56-63. doi: 10.1016/S1473-3099(21)00479-5. Epub 2021 Sep 9.
3
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
Lancet Infect Dis. 2024 Apr;24(4):351-360. doi: 10.1016/S1473-3099(23)00650-3. Epub 2023 Dec 20.
4
Safety Profile and Low Risk of Disease Relapse After BNT162b2 mRNA SARS-CoV-2 Vaccination in Patients With Rare Rheumatic Diseases.
J Rheumatol. 2022 Mar;49(3):334-335. doi: 10.3899/jrheum.210863. Epub 2022 Jan 15.
5
Immediate reactions after mRNA SARS-CoV-2 vaccination.
CMAJ. 2021 Dec 6;193(48):E1842. doi: 10.1503/cmaj.211581. Epub 2021 Nov 12.
6
Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac).
J Infect. 2023 Mar;86(3):256-308. doi: 10.1016/j.jinf.2022.12.016. Epub 2022 Dec 17.
7
Comparative Safety of the BNT162b2 Messenger RNA COVID-19 Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years.
JAMA Netw Open. 2022 Oct 3;5(10):e2237140. doi: 10.1001/jamanetworkopen.2022.37140.
8
Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.
J Am Soc Nephrol. 2022 Jan;33(1):49-57. doi: 10.1681/ASN.2021060778. Epub 2021 Nov 17.
9
Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study.
Dig Liver Dis. 2023 Feb;55(2):160-168. doi: 10.1016/j.dld.2022.09.010. Epub 2022 Oct 17.
10
Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Lancet Healthy Longev. 2022 Mar;3(3):e166-e175. doi: 10.1016/S2666-7568(22)00012-5. Epub 2022 Feb 23.
引用本文的文献
1
Changes in haemostasis and inflammatory markers after mRNA BNT162b2 and vector Ad26.CoV2.S SARS-CoV-2 vaccination.
Thromb Res. 2023 Aug;228:137-144. doi: 10.1016/j.thromres.2023.06.008. Epub 2023 Jun 14.
2
Head-to-head comparison of four COVID-19 vaccines on platelet activation, coagulation and inflammation. The TREASURE study.
Thromb Res. 2023 Mar;223:24-33. doi: 10.1016/j.thromres.2023.01.015. Epub 2023 Jan 18.
3
COVID-19 mRNA vaccine-associated cerebral venous thrombosis: Rare adverse event or coincidence?
Am J Hematol. 2023 Jan;98(1):E4-E7. doi: 10.1002/ajh.26773. Epub 2022 Nov 10.
本文引用的文献
1
No changes of parameters nor coagulation activation in healthy subjects vaccinated for SARS-Cov-2.
Thromb Update. 2021 Aug;4:100059. doi: 10.1016/j.tru.2021.100059. Epub 2021 Jun 25.
2
Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study.
Lancet. 2021 Sep 25;398(10306):1147-1156. doi: 10.1016/S0140-6736(21)01608-1. Epub 2021 Aug 6.
3
Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study.
Thromb Res. 2021 Sep;205:24-28. doi: 10.1016/j.thromres.2021.06.016. Epub 2021 Jun 25.
4
Cerebral venous thrombosis post BNT162b2 mRNA SARS-CoV-2 vaccination: A black swan event.
Am J Hematol. 2021 Sep 1;96(9):E357-E361. doi: 10.1002/ajh.26272. Epub 2021 Jun 26.
5
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination.
N Engl J Med. 2021 Jun 10;384(23):2202-2211. doi: 10.1056/NEJMoa2105385. Epub 2021 Apr 16.
6
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination.
N Engl J Med. 2021 May 20;384(20):1964-1965. doi: 10.1056/NEJMc2105869. Epub 2021 Apr 14.
7
COVID-19 associated coagulopathy in critically ill patients: A hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis.
J Thromb Thrombolysis. 2021 Apr;51(3):663-674. doi: 10.1007/s11239-020-02318-x. Epub 2020 Oct 24.
8
Elevated Expression of Serum Endothelial Cell Adhesion Molecules in COVID-19 Patients.
J Infect Dis. 2020 Aug 17;222(6):894-898. doi: 10.1093/infdis/jiaa349.
9
ISTH interim guidance on recognition and management of coagulopathy in COVID-19.
J Thromb Haemost. 2020 May;18(5):1023-1026. doi: 10.1111/jth.14810. Epub 2020 Apr 27.
Zotero 插件